Journal of Gastroenterology · 2018 · 24 citations · 37 references
Public HealthBiostatisticsInternal MedicineClinical EpidemiologyEpidemiologySurvival AnalysisComparative Mortality AnalysisInflammatory Bowel DiseaseLife Table AnalysisLife Table MethodsMortality AnalysisMortality MeasurementCohort Study InvestigationLife Table ParametersStandardized Mortality RatesStandardized Mortality StatisticsSurvival Rate EstimationSurvival Rates
BACKGROUND: In this study, survival and cause of death were investigated in patients with Crohn's disease (CD) at a tertiary referral center. METHODS: A database was created based on the medical records of 1108 CD patients who had a history of visiting our hospital to investigate background characteristics, cumulative survival rates from diagnosis, causes of death, and the standardized mortality ratio (SMR) for each cause of death. A follow-up questionnaire survey of patients followed up inadequately was also conducted. The cumulative survival rate from diagnosis was determined using the life table method and compared with that of a sex- and age-matched population model from the year 2000. RESULTS: The study included 1108 patients whose mean age at diagnosis was 25.6 ± 10.8 years. The mean duration of follow-up was 14.6 ± 9.4 years, and there were 52 deaths. The cumulative survival rate was significantly lower 25 years after the diagnosis of CD (91.7%) than in the standard population model (95.7%). SMRs for both all causes [3.5; 95% confidence interval (CI): 2.7-4.6] and CD-specific causes (36.7; 95% CI 26.1-51.6) were high. Among the CD-specific causes, SMRs were especially high for small intestine and colorectal cancers, gastrointestinal diseases including intestinal failure (IF), perioperative complications, and amyloidosis. CONCLUSION: The SMRs for both all causes and CD-specific causes were high in CD patients. CD-specific causes including intestinal cancer, IF, perioperative complications, and amyloidosis showed especially high SMRs.
37
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Mark S. Silverberg, Jack Satsangi, Tariq Ahmad et al. · Canadian Journal of Gastroenterology · 2005 · 3.4K citations · Full text
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands, Frank Anderson, Çharles N. Bernstein et al. · New England Journal of Medicine · 2004 · 2.2K citations · Full text
Tine Jess, Lene Riis, Ida Vind et al. · Inflammatory Bowel Diseases · 2006 · 393 citations · Full text